255 related articles for article (PubMed ID: 8407393)
1. Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: a comparison of short versus long intravenous dose schedules (RTOG 86-12).
Urtasun RC; Cosmatos D; DelRowe J; Kinsella TJ; Lester S; Wasserman T; Fulton DS
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):207-14. PubMed ID: 8407393
[TBL] [Abstract][Full Text] [Related]
2. Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, Phase I-II study.
Urtasun RC; Kinsella TJ; Farnan N; DelRowe JD; Lester SG; Fulton DS
Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1163-7. PubMed ID: 8985039
[TBL] [Abstract][Full Text] [Related]
3. National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma.
Sullivan FJ; Herscher LL; Cook JA; Smith J; Steinberg SM; Epstein AH; Oldfield EH; Goffman TE; Kinsella TJ; Mitchell JB
Int J Radiat Oncol Biol Phys; 1994 Oct; 30(3):583-90. PubMed ID: 7928489
[TBL] [Abstract][Full Text] [Related]
4. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.
Schulz CA; Mehta MP; Badie B; McGinn CJ; Robins HI; Hayes L; Chappell R; Volkman J; Binger K; Arzoomanian R; Simon K; Alberti D; Feierabend C; Tutsch KD; Kunugi KA; Wilding G; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1107-15. PubMed ID: 15234045
[TBL] [Abstract][Full Text] [Related]
5. 5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
Vokes EE; Dolan ME; Krishnasamy S; Mick R; Ratain MJ; Berezin F; Brachman D; Whitman G; Schilsky RL; Charette J
Ann Oncol; 1993 Aug; 4(7):591-5. PubMed ID: 8395874
[TBL] [Abstract][Full Text] [Related]
6. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
[TBL] [Abstract][Full Text] [Related]
7. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme.
Jackson D; Kinsella T; Rowland J; Wright D; Katz D; Main D; Collins J; Kornblith P; Glatstein E
Am J Clin Oncol; 1987 Oct; 10(5):437-43. PubMed ID: 2821790
[TBL] [Abstract][Full Text] [Related]
8. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Nelson DF; Curran WJ; Scott C; Nelson JS; Weinstein AS; Ahmad K; Constine LS; Murray K; Powlis WD; Mohiuddin M
Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):193-207. PubMed ID: 8380567
[TBL] [Abstract][Full Text] [Related]
9. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
Levin VA; Prados MR; Wara WM; Davis RL; Gutin PH; Phillips TL; Lamborn K; Wilson CB
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):75-83. PubMed ID: 7721642
[TBL] [Abstract][Full Text] [Related]
10. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
Chang EL; Loeffler JS; Riese NE; Wen PY; Alexander E; Black PM; Coleman CN
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):65-70. PubMed ID: 9422559
[TBL] [Abstract][Full Text] [Related]
11. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer.
Kinsella TJ; Russo A; Mitchell JB; Collins JM; Rowland J; Wright D; Glatstein E
Int J Radiat Oncol Biol Phys; 1985 Nov; 11(11):1941-6. PubMed ID: 2997090
[TBL] [Abstract][Full Text] [Related]
13. Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study.
Fulton DS; Urtasun RC; Scott-Brown I; Johnson ES; Mielke B; Curry B; Huyser-Wierenga D; Hanson J; Feldstein M
J Neurooncol; 1992 Sep; 14(1):63-72. PubMed ID: 1335044
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme.
Kinsella TJ; Collins J; Rowland J; Klecker R; Wright D; Katz D; Steinberg SM; Glastein E
J Clin Oncol; 1988 May; 6(5):871-9. PubMed ID: 2835444
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
[TBL] [Abstract][Full Text] [Related]
16. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma.
Dillman RO; Shea WM; Tai DF; Mahdavi K; Barth NM; Kharkar BR; Poor MM; Church CK; DePriest C
Neuro Oncol; 2001 Jan; 3(1):35-41. PubMed ID: 11305415
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
19. High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison.
Tanaka M; Ino Y; Nakagawa K; Tago M; Todo T
Lancet Oncol; 2005 Dec; 6(12):953-60. PubMed ID: 16321763
[TBL] [Abstract][Full Text] [Related]
20. Randomized neutron dose searching study for malignant gliomas of the brain: results of an RTOG study. Radiation Therapy Oncology Group.
Laramore GE; Diener-West M; Griffin TW; Nelson JS; Griem ML; Thomas FJ; Hendrickson FR; Griffin BR; Myrianthopoulos LC; Saxton J
Int J Radiat Oncol Biol Phys; 1988 Jun; 14(6):1093-102. PubMed ID: 2838442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
